Recent News

• 03.05.2025 - TNF Pharmaceuticals to Host Investor Conference Call and Webcast Featuring Clinical Scientific Updates on Thursday, March 6, 2025
• 02.25.2025 - TNF Pharmaceuticals Initiates Phase 2b Clinical Trial of First Oral TNF-Alpha Inhibitor
• 01.29.2025 - TNF Pharmaceuticals Launches Study Series Aimed at Preserving Lean Muscle Mass During GLP-1 Weight Loss Treatment
• 01.15.2025 - TNF Pharmaceuticals Announces Positive Clinical Data Supporting Clinical Trial Expansion
• 12.19.2024 - TNF Pharmaceuticals Announces Trial to Explore Effects of Lead Candidate in Sarcopenia/Frailty Induced by GLP-1 Weight Loss Drugs
• 12.09.2024 - TNF Pharmaceuticals Presents Statistically Significant Phase 2a Trial Results for Novel Sarcopenia/Frailty Treatment at Prestigious International Conference
• 10.02.2024 - TNF Pharmaceuticals Announces Strategic Equity Investment Priced at a Premium to Market
• 08.21.2024 - TNF Pharmaceuticals Prepares to Advance Lead Clinical Program Targeting Age-Related Decline

Recent Filings

• 11.26.2024 - 8-K Current report
• 11.14.2024 - SC 13G/A Statement of Beneficial Ownership by Certain Investors
• 11.14.2024 - 10-Q Quarterly report [Sections 13 or 15(d)]
• 11.01.2024 - ARS Annual Report to Security Holders
• 11.01.2024 - DEF 14A Other definitive proxy statements
• 10.07.2024 - EX-99.1 EX-99.1
• 10.07.2024 - UPLOAD SEC-generated letter
• 10.07.2024 - 8-K Current report
• 10.04.2024 - 8-K Current report
• 09.30.2024 - CORRESP Correspondence